Urabe Fumihiko
Dr. Fumihiko Urabe is a Clinical Associate of Urology, and his research is focused on liquid biopsy (circulating miRNAs) and extracellular vesicles (EVs) in urological cancers. In liquid biopsy research, he established models based on combinations of circulating microRNAs to detect prostate cancer and bladder cancer with high sensitivity and specificity by using large-scale microarray analyses (Urabe et al. Clin Cancer Res. 2019; Usuba and Urabe et al. Cancer Sci. 2019). As the first author and first co-author of each paper, he demonstrated that circulating microRNAs could be a practical novel detection method for urological cancers, and these studies were selected as highlights of their respective journal issues.
In EV research, he provided a novel insight into microRNA-mediated tumor suppression by inhibiting EV biogenesis. EVs, which have recently garnered attention, are known for their role in cancer progression; however, the secretion mechanisms of EVs in prostate cancer and their contribution to cancer progression have not been elucidated. The results of his study offered further understanding of cancer development and proposed novel approaches for prostate cancer treatment (Urabe et al., Science Advances. 2020; Urabe et al., Cancer Science. 2021). Additionally, in the mechanism of bone metastasis progression in prostate cancer, he reported that the properties and quantity of EVs exchanged between prostate cancer and the surrounding bone microenvironment have a significant impact (Urabe et al., J Extracell Vesicles. 2023, Ito et al. Mol Oncol. 2023).
Through his Ph.D. course, he learned that both basic research and translational research are important to establish future cancer therapeutic strategies. Additionally, he experienced the significance of collaboration with individuals from diverse backgrounds, such as physicians, biologists, computer scientists, and others. Furthermore, he realized that his motivation for research stems from a desire to contribute to cancer patients by delivering the science of basic research for their treatment. Currently, he is aiming to become a physician-scientist, engaging in surgery and education as a clinician while advancing clinical papers and basic research.
To date he has received numerous prestigious awards and recognitions for his research from the American Urological Association (AUA), the Japanese Cancer Association (JCA), and the Japanese Urological Association (JUA), among others. He has published over 120 scientific papers in peer-reviewed journals and has presented his research at national and international conferences.
15th August 2025
| Time | Session |
|---|---|
|
12:00
13:00
|
Integrating Radioligand Therapy into mCRPC Clinical Practice: From Taiwan and Japan Experience
TICC - 2F 201BC
|
16th August 2025
| Time | Session |
|---|---|
|
12:00
13:00
|
Latest Advances in mHSPC to Fight Tumor Heterogeneity: Experience from Australia and Japan
TICC - 3F South Lounge
|